Heart Monitoring a Must for Breast Cancer Patients on Herceptin

Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Cardiology, Gynecology, Oncology, Pharmacy, Preventive Medicine, News, Source Type: news

Related Links:

Cancer therapy decisions are often made according to the histopathological-molecular profile of tumor tissue obtained from surgery or biopsy. It has been shown that tumor profiles change with time and treatment, and that tumor tissue is heterogeneous. Thus, other approaches that are easily accessible and less invasive than surgery or biopsy to monitor responses to treatment and predict relapses are urgently needed. In the last few years, the term “liquid biopsies” has been introduced to represent multifunctional circulating biomarkers in the peripheral blood and other physiological fluids of patients with cance...
Source: Oncology - Category: Cancer & Oncology Source Type: research
Conclusion This single-center study showed that in patients with BC, a combination of functional and anatomical data that were obtained by using SPECT-CT with 99mTc-MIBI can significantly improve detectability of multiple (>2) axillary metastases.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: ORIGINAL ARTICLES Source Type: research
Publication date: Available online 16 January 2019Source: Materials Science and Engineering: CAuthor(s): Camila dos Santos Chagas, Fernando L.A. Fonseca, Izilda A. BagatinAbstractQuinoline-derivative coordination compounds were synthesized with Zn(II), Al(III), Cu(II), Ru(II) producing 1–4 compounds using 5-nitro-8-hydroxyquinoline and 5–8 compounds using 5-chloro-8-hydroxyquinoline. These coordination compounds were characterized by elemental analysis and 1H NMR, IR, UV–vis and fluorescence spectroscopies, representing the coherent data matched all compounds. Myelotoxicity data, as well as the biochemica...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer, Published online: 17 January 2019; doi:10.1038/s41416-018-0349-6Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
In this study, we evaluated the efficacy of varlitinib, a reversible small molecule pan-HER inhibitor in TNBC. Our results showed that varlitinib reduced cell viability and induced cell apoptosis in most TNBC cell lines but not in MDA-MB-231 cells. MEK and ERK inhibition overcame resistance to varlitinib in MDA-MB-231 cells. Varlitinib inhibited HER signaling which led to inhibition of migration, invasion and mammosphere formation of TNBC cells as well as significant suppression of tumor growth of MDA-MB-468 xenograft mouse model. In summary, these results suggest that HER signaling plays an important role in TNBC progress...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractIntroductionWith evolving treatment guidelines for germlineBRCA1/2 mutation (gBRCAm) in breast cancer, we present the latest gBRCA testing rates among metastatic breast cancer (mBC) patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2 −) or triple-negative breast cancer (TNBC). Among these patients with gBRCAm, we analyzed clinical outcomes, treatment patterns, and health resource utilization (HRU).MethodsThe Flatiron Health electronic health record database was used to assess gBRCA testing rates in a real-world retrospective analysis of US patients at least 18 &...
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
ConclusionsWe observed that an increasing proportion of women are using ET for LCIS management, but geographical differences exist. Health insurance status played an important role in the underutilization of ET. Further research is needed to assess patient outcomes given the variations in management of LCIS.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
ConclusionsThis is the most extensive analysis of palbociclib in ≥ 4th-line setting. Clinical benefit was confirmed particularly for endocrine-sensitive, predominantly bony disease and in earlier lines of treatment. Safety was similar to PALOMA trials with higher febrile neutropenia rate.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractPurpose of ReviewBreast density, or the amount of fibroglandular tissue in the breast, has become a recognized and independent marker for breast cancer risk. Public awareness of breast density as a possible risk factor for breast cancer has resulted in legislation for risk stratification purposes in many US states. This review will provide a comprehensive overview of the currently available imaging modalities for qualitative and quantitative breast density assessment and the current evidence on breast density and breast cancer risk assessment.Recent FindingsTo date, breast density assessment is mainly performed wit...
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research
AbstractMembrane overexpression of ErbB-2 (MErbB-2), a member of the ErbB family of receptor tyrosine kinases, occurs in 15 –20% of breast cancers (BC) and constitutes a therapeutic target in this BC subtype (ErbB-2-positive). Although MErbB-2-targeted therapies have significantly improved patients’ clinical outcome, resistance to available drugs is still a major issue in the clinic. Lack of accurate biomarkers for p redicting responses to anti-ErbB-2 drugs at the time of diagnosis is also an important unresolved issue. Hence, a better understanding of the ErbB-2 signaling pathway constitutes a critical task in...
Source: Hormones and Cancer - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Heart | Herceptin